Investigating Myosteatosis in Steatotic Liver Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-22

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities : metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD) and a mixed entity combining the two settings referred as MetALD. SLD are associated to extra-hepatic complications such as cardiovascular diseases, insulin resistance or muscle changes. Among the latter, myosteatosis, defined by an excessive muscle fat content, has been reported as a muscle change in MASLD occuring even in non-cirrhotic stages. Investigators will explore these muscle changes in SLD patients according to the severity of the underneath liver disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Cohort Study in Patients With NAFLD

NCT00575133

Non-alcoholic Fatty Liver Disease

RECRUITING

Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis

NCT01324414

Non Alcoholic Fatty Liver Diseases (NAFLD)

COMPLETED

Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients

NCT06814600

NAFLD Inflammatory Bowel Diseases Steatosis +1 more

RECRUITING

Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI)

NCT01234701

Neoplasms

COMPLETED

Exploratory Study of MRI Biomarkers of NASH

NCT06626074

Non-alcoholic Fatty Liver Disease NAFLD

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project investigates the correlation between liver and muscle phenotypes assessed in a cohort of all 3 SLD subgroups (MASLD, ALD and MetALD). If a severe form of SLD is suspected based on a severely increased liver elasticity, assessed by transient elastography, participants undergo a liver biopsy, liver and muscle magnetic resonance imaging. Eating habits and physical activity level are recorded using the 24 hour-recall and international physical activity questionnaire. Psychological disorders are also screened using dedicated questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol-related Liver Disease Metabolic Dysfunction Associated Steatotic Liver Disease Steatotic Liver Disease of Mixed Origin (MetALD) Steatotic Liver Diseases Myosteatosis Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Liver Histology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MASLD patients

patients presenting with liver steatosis and at least one cardiometabolic criteria.

No interventions assigned to this group

ALD patients

patients presenting with liver steatosis secondary to an excessive consumption of alcoholic beverages and with no cardiometabolic criteria.

No interventions assigned to this group

MetALD patients

patients presenting with liver steatosis, at least one cardiometabolic criteria and an excessive consumption of alcohol beverages.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between18 to 75 years
* Presence of hepatic steatosis, suggested by a controlled attenuation parameter (CAP) ≥ 252 dB/m on elastometry and elevated transaminases (ALT ≥ 25 or 33 IU/L in women or men respectively)
* Presence of overweight (BMI \> 25 kg/m²), obesity (BMI \> 30 kg/m²), metabolic syndrome, prediabetes or type 2 diabetes. Metabolic syndrome is defined by int ernational Diabetes Federation as follows : waist circumference ≥ 94/80cm for men/women with ≥ 2 other criteria: arterial pressure ≥ 130/85 mmHg or treatment for hypertension, fasting glucose ≥ 130/85 mmHg or treatment for hypertension, serum triglycerides \> 150 mg/dl or treatment for dyslipidemia, HDL cholesterol \< 40/50 mg/dl for men/women or treatment for dyslipidemia.

Exclusion Criteria

* Liver disease from other causes (alcohol, active viral chronic hepatitis B or C, Wilson\'s disease, autoimmune hepatitis, alpha1-anti-trypsin deficiency,...)
* Heavy consumption of alcoholic beverages, i.e. \> 140 g or 210 g of ethanol in women or men respectively).
* Intravenous drug use
* HbA1C \> 10%
* Decompensated cirrhosis (presence of ascites, bilirubin level \> 1.2 mg/dL in a patient without Gilbert's syndrome, albumin level \< 35 g/L)
* Pregnancy
* Use of drugs that may cause steatosis (methotrexate, amiodarone, tamoxifen, oral corticosteroids) currently or in the last 3 months
* Change in treatment of hyperglycaemia (dose or medication) in the last 3 months
* Change in body weight \>5% in the last 3 months
* Active cancer
* End stage renal disease or dialysis
* Type 1 diabetes or secondary diabetes
* Digestive malabsorption
* Untreated thyroid disease
* Taking a treatment under study or approved for NASH (semaglutide, lanifibranor, obeticholic acid).
* Musculoskeletal disorders, neuromuscular or inflammatory diseases such as connective tissue diseases, myositis and vasculitis that have musculoskeletal manifestations.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes